Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): examining health care staff attitudes during a hybrid III implementation-effectiveness trial implementing cabotegravir plus rilpivirine long-acting injectable (CAB plus RPV LA) for people living with HIV (PLHIV)

C. Gutner; S. Dakhia; M. Gill; M. Pascual-Bernaldez; B. Hernandez; A. Rami; J. Portilla; T. Lutz; M. van der Valk; E. Florence; N. Barnes; O. Cooper; D. Filipenko; A. Hamilton; M. Bosse; M. Czarnogorski

Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): examining health care staff attitudes during a hybrid III implementation-effectiveness trial implementing cabotegravir plus rilpivirine long-acting injectable (CAB plus RPV LA) for people living with HIV (PLHIV)

C. Gutner, S. Dakhia, M. Gill, M. Pascual-Bernaldez, B. Hernandez, A. Rami, J. Portilla, T. Lutz, M. van der Valk, E. Florence, N. Barnes, O. Cooper, D. Filipenko, A. Hamilton, M. Bosse, M. Czarnogorski

Research output: Contribution to journal › Conference abstract in journal

Original language	English
Article number	PE2/56
Journal	HIV Medicine
Volume	22
Issue number	S3
Pages (from-to)	114-115
Number of pages	2
ISSN	1464-2662
Publication status	Published - 2021

Cite this

Gutner, C., Dakhia, S., Gill, M., Pascual-Bernaldez, M., Hernandez, B., Rami, A., Portilla, J., Lutz, T., van der Valk, M., Florence, E., Barnes, N., Cooper, O., Filipenko, D., Hamilton, A., Bosse, M., & Czarnogorski, M. (2021). Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): examining health care staff attitudes during a hybrid III implementation-effectiveness trial implementing cabotegravir plus rilpivirine long-acting injectable (CAB plus RPV LA) for people living with HIV (PLHIV). HIV Medicine, 22(S3), 114-115. Article PE2/56.

Gutner, C. ; Dakhia, S. ; Gill, M. et al. / Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): examining health care staff attitudes during a hybrid III implementation-effectiveness trial implementing cabotegravir plus rilpivirine long-acting injectable (CAB plus RPV LA) for people living with HIV (PLHIV). In: HIV Medicine. 2021 ; Vol. 22, No. S3. pp. 114-115.

@article{d47de8bfe2994b1bbb983ade7510617b,

title = "Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): examining health care staff attitudes during a hybrid III implementation-effectiveness trial implementing cabotegravir plus rilpivirine long-acting injectable (CAB plus RPV LA) for people living with HIV (PLHIV)",

author = "C. Gutner and S. Dakhia and M. Gill and M. Pascual-Bernaldez and B. Hernandez and A. Rami and J. Portilla and T. Lutz and {van der Valk}, M. and E. Florence and N. Barnes and O. Cooper and D. Filipenko and A. Hamilton and M. Bosse and M. Czarnogorski",

note = "NPP",

year = "2021",

language = "English",

volume = "22",

pages = "114--115",

journal = "HIV Medicine",

issn = "1464-2662",

publisher = "John Wiley & Sons",

number = "S3",

}

Gutner, C, Dakhia, S, Gill, M, Pascual-Bernaldez, M, Hernandez, B, Rami, A, Portilla, J, Lutz, T, van der Valk, M, Florence, E, Barnes, N, Cooper, O, Filipenko, D, Hamilton, A, Bosse, M & Czarnogorski, M 2021, 'Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): examining health care staff attitudes during a hybrid III implementation-effectiveness trial implementing cabotegravir plus rilpivirine long-acting injectable (CAB plus RPV LA) for people living with HIV (PLHIV)', HIV Medicine, vol. 22, no. S3, PE2/56, pp. 114-115.

Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): examining health care staff attitudes during a hybrid III implementation-effectiveness trial implementing cabotegravir plus rilpivirine long-acting injectable (CAB plus RPV LA) for people living with HIV (PLHIV). / Gutner, C.; Dakhia, S.; Gill, M. et al.
In: HIV Medicine, Vol. 22, No. S3, PE2/56, 2021, p. 114-115.

Research output: Contribution to journal › Conference abstract in journal

TY - JOUR

T1 - Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): examining health care staff attitudes during a hybrid III implementation-effectiveness trial implementing cabotegravir plus rilpivirine long-acting injectable (CAB plus RPV LA) for people living with HIV (PLHIV)

AU - Gutner, C.

AU - Dakhia, S.

AU - Gill, M.

AU - Pascual-Bernaldez, M.

AU - Hernandez, B.

AU - Rami, A.

AU - Portilla, J.

AU - Lutz, T.

AU - van der Valk, M.

AU - Florence, E.

AU - Barnes, N.

AU - Cooper, O.

AU - Filipenko, D.

AU - Hamilton, A.

AU - Bosse, M.

AU - Czarnogorski, M.

N1 - NPP

PY - 2021

Y1 - 2021

M3 - Conference abstract in journal

SN - 1464-2662

VL - 22

SP - 114

EP - 115

JO - HIV Medicine

JF - HIV Medicine

IS - S3

M1 - PE2/56

ER -

Gutner C, Dakhia S, Gill M, Pascual-Bernaldez M, Hernandez B, Rami A et al. Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): examining health care staff attitudes during a hybrid III implementation-effectiveness trial implementing cabotegravir plus rilpivirine long-acting injectable (CAB plus RPV LA) for people living with HIV (PLHIV). HIV Medicine. 2021;22(S3):114-115. PE2/56.